Founded with the mission to revolutionize tissue assessment, Aquyre Biosciences leverages proprietary technologies to provide non-invasive, non-destructive, intraprocedural tissue adequacy assessments. Their core product combines Full-Field Optical Coherence Tomography (FFOCT) and other imaging techniques to deliver high-resolution, 3D imaging of tissue micro-architecture within two minutes. This rapid and precise assessment aids medical professionals in identifying various cell types, including cancer cells, thus enhancing biopsy sample evaluation. The company primarily focuses on the healthcare market, particularly in areas requiring quick and accurate tissue diagnostics.
Notable affiliated individuals include Dr. Wilson Tsai, Director of the Thoracic Program at John Muir Health, who supports the clinical applications of Aquyre's technology. The company has garnered attention for its significant contributions to lung biopsy procedures, becoming an industry leader in this niche. By enabling quicker and more accurate tissue assessments, Aquyre Biosciences has made a substantial impact on pathology workflows and patient outcomes, helping prioritize specimens for further examination and improving diagnostic accuracy.
CellTivity Scientific's most recent funding round was for $5.4M (USD) in March 2022.
As of Mar 9, 2022, CellTivity Scientific has disclosed funding of $22.6M (USD).

Akoya Biosciences
akoyabio.com

ClearLight Biotechnologies

QuantumCyte
quantumcyte.com
Aqueous Biomedical

ViOptix
vioptix.com

Pathware
pathware.com

Instapath
instapathbio.com

LighTopTech
lightoptech.com
Vitra Bioscience

Quantificare
quantificare.com

Ultivue

Aqtual
aqtual.com

Standard BioTools
standardbio.com

RareCyte
rarecyte.com

AccuraGen

Akrivis Technologies
akrivis.com

Aurita
auritabio.com

SevenOaks BioSystems

BioFluidica
biofluidica.com
Triopsy Medical
3dbiopsy.com